Company Short-Term Debts: Mereo BioPharma Group PLC (MREO)

Graphic logo of Mereo BioPharma (MREO)

Mereo BioPharma (MREO) develops innovative therapies for orphan diseases, leveraging strategic alliances with global pharma behemoths to conduct final trials. Stock price volatility reflects the dynamics of debt obligations, where the indicator stands at 0.00. Growth prospects depend on the streamlined transport of drugs via specialized cold chains, ensuring material integrity within international programs.

MREO (Mereo BioPharma) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

MREO (Mereo BioPharma Group): analytical breakdowns and indicator data

- price and consensus price forecast:
Stock Price Mereo BioPharma Group PLC|MREO - Consensus Target
- market capitalization data:
Market Capitalization Mereo BioPharma Group plc|MREO - Company Buyout Price
- book capitalization data:
Book Value per Share Mereo BioPharma|MREO - Book Capitalization|Market Value to Book Value Ratio mereobiopharma.com|MREO - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Mereo BioPharma|MREO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Mereo BioPharma Group PLC|MREO - Company Aggregate Indebtedness|Debts to Book Capitalization Mereo BioPharma Group plc|MREO - Long-Term Debt|Company Short-Term Debts Mereo BioPharma
Analysis of all company metrics:mereobiopharma.com, MREO
Product sample of Mereo BioPharma

Liquidity management is critical for Mereo BioPharma (MREO) when implementing costly research into rare diseases. This metric aggregates all financial obligations with a maturity of up to twelve months. By analyzing the dynamics of the company's short-term debt, an investor assesses the business's ability to service current loans without external support. Given the dependence on partner payments, such a metric reveals the risk of cash flow gaps. A stable balance sheet confirms the issuer's resilience to delays in clinical trials.

Competitors of Mereo BioPharma (MREO)

VRTX: Company Short-Term Debts|ALNY - Company Current Liabilities|Insmed Inc - Company Short-Term Debts|United Therapeutics Inc. (UTHR) - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts BBIO|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt Cogent Biosciences Inc (COGT)|Company Short-Term Debts XERS|KROS - Short-Term Debt Volume|Company Current Liabilities Arcturus Therapeutics|ETON - Current Liabilities|Company Short-Term Debts KMDA|Fulcrum Therapeutics Inc (FULC) - Short-Term Debt|Company Short-Term Debts Abeona Therapeutics, Inc. (ABEO)|Company Short-Term Indebtedness Protalix BioTherapeutics, Inc (PLX)|Pliant Therapeutics (PLRX) - Company Current Liabilities|Company Short-Term Loans and Borrowings APLT (Applied Therapeutics Inc.)|Rein Therapeutics (RNTX) - Company Short-Term Debt|Current Liabilities Gelteq Ltd GELS|Company Short-Term Debts Aytu Therapeutics (AYTU)|CMMB - Company Short-Term Loans and Borrowings|SRXH: Company Short-Term Debts|PLRZ (Polyrizon) - Company Short-Term Debts|AEZS - Company Short-Term Debt|Company Short-Term Loans and Borrowings CYTH|Company Short-Term Debt INZY (Inozyme Pharma, Inc.)|Company Current Liabilities Reneo Pharmaceuticals, Inc (RPHM)|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)